Across TCGA pan-cancer cohorts, SELENOM mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SELENOM data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher SELENOM mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SELENOM expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

LSCC, CCRCC, and PDAC are the cancer types where SELENOM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.442	0.897	<.001	49	view →
CCRCC	OS	Tertile	All	0.722	0.929	.021	9	view →
PDAC	OS	Quartile	All	0.606	0.337	.034	6	view →
HNSC	DFS	Tertile	IV	0.547	0.824	.042	3	view →
UCEC	DFS	Median	All	0.952	0.859	.031	2	view →
GBM	DFS	Median	All	0.302	0.456	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: SELENOM tumor-vs-normal RNA expression · all SELENOM data types